Human CD27 Ligand/TNFSF7 Antibody Summary
Gln45-Pro193
Accession # AAA36175
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Scientific Data
View Larger
Detection of CD27Ligand/TNFSF7 in HEK293 Human Cell Line Transfected with Human CD27 Ligand/TNFSF7 by Flow Cytometry. HEK293 human embryonic kidney cell line transfected with human CD27 Ligand/TNFSF7 (filled histogram) or irrelevant protein (open histogram) was stained with Mouse Anti-Human CD27 Ligand/TNFSF7 Monoclonal Antibody (Catalog # MAB2738) followed by Goat anti-mouse PE-conjugated secondary antibody (F0102B). Staining was performed using our Staining Membrane-associated Proteins protocol.
View Larger
Detection of CD27 Ligand/TNFSF7 by Western Blot Experimental setup and the effect of PHD3 silencing on 786-O proteome. a siRNA-mediated silencing of PHD3 protein level in 786-O ccRCC cell line using two individual siRNA sequences in normoxic and in hypoxic (1% O2) condition. Quantification of three biological replicates, mean ± SEM, fold change to control (Scr). Asterisk indicates a statistically significant difference (*p < 0.05, **p < 0.01). b siRNA-mediated silencing of PHD3 mRNA expression, quantification of three individual experiments. Mean ± SEM, fold change to Scr (***p < 0.001). c Flow chart of the experimental procedure. 786-O cells were transfected with siPHD3#1 or with a non-targeting control siRNA (Scr) for 24 h followed by a hypoxic (1% O2) or normoxic (21% O2) exposure. Three independent experiments were performed; proteins were extracted, followed by in-gel digestion with trypsin. Purified peptides were ran through mass spectrometer. Protein identification was done with Mascot database search. Protein quantification was carried out with Progenesis QI, followed by testing the differential expression between sample groups using peptide-level expression change averaging (PECA). d Western blot validations of selected proteins in 786-O and RCC4 cell lines with two individual siRNA sequences targeting PHD3, representative analyses are shown Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/28680592), licensed under a CC-BY license. Not internally tested by R&D Systems.
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: CD27 Ligand/TNFSF7
CD27 Ligand is a member of the tumor necrosis factor superfamily (TNFSF7) and is also designated CD70. CD27 Ligand is a type II transmembrane protein expressed by activated T and B cells. It binds to CD27 on mature T cells and a subset of thymocytes. CD27 Ligand induces the proliferation of costimulated T cells and enhances the generation of cytolytic T cells.
Product Datasheets
Citations for Human CD27 Ligand/TNFSF7 Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
12
Citations: Showing 1 - 10
Filter your results:
Filter by:
-
CD70 antibody‐drug conjugate: A potential novel therapeutic agent for ovarian cancer
Authors: Mayu Shiomi, Shinya Matsuzaki, Satoshi Serada, Koji Matsuo, Chihiro Mizuta‐Odani, Mariko Jitsumori et al.
Cancer Science
-
HIF prolyl hydroxylase PHD3 regulates translational machinery and glucose metabolism in clear cell renal cell carcinoma
Authors: Miikkulainen P, Hogel H, Rantanen K et al.
Cancer Metab
-
Molecular Characterization of the Tumor Microenvironment in Renal Medullary Carcinoma
Authors: David S. Tourigny, Mark Zucker, Minsoo Kim, Paul Russo, Jonathan Coleman, Chung-Han Lee et al.
Frontiers in Oncology
-
Soluble CD27 differentially predicts resistance to anti-PD1 alone but not with anti-CTLA-4 in melanoma
Authors: Sam, I;Benhamouda, N;Biard, L;Da Meda, L;Desseaux, K;Baroudjan, B;Nakouri, I;Renaud, M;Sadoux, A;Alkatrib, M;Deleuze, JF;Battistella, M;Shen, Y;Resche-Rigon, M;Mourah, S;Lebbe, C;Tartour, E;
EMBO molecular medicine
Species: Human
Sample Types: Whole Tissue
Applications: Immunohistochemistry -
CD28 costimulation augments CAR signaling in NK cells via the LCK/CD3Z/ZAP70 signaling axis
Authors: Acharya, S;Basar, R;Daher, M;Rafei, H;Li, P;Uprety, N;Ensley, E;Shanley, M;Kumar, B;Banerjee, PP;Melo Garcia, L;Lin, P;Mohanty, V;Kim, KH;Jiang, X;Pan, Y;Li, Y;Liu, B;Nunez Cortes, AK;Zhang, C;Fathi, M;Rezvan, A;Montalvo, MJ;Cha, SL;Reyes-Silva, F;Shrestha, R;Guo, X;Kundu, K;Biederstadt, A;Muniz-Feliciano, L;Deyter, GM;Kaplan, M;Jiang, XR;Liu, E;Jain, A;Roszik, J;Fowlkes, NW;Solis Soto, LM;Raso, MG;Khoury, JD;Lin, P;Vega, F;Varadarajan, N;Chen, K;Marin, D;Shpall, EJ;Rezvani, K;
Cancer discovery
Species: Human
Sample Types: Whole Tissue
Applications: Immunohistochemistry -
IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts
Authors: Van den Eynde, A;Gehrcken, L;Verhezen, T;Lau, HW;Hermans, C;Lambrechts, H;Flieswasser, T;Quatannens, D;Roex, G;Zwaenepoel, K;Marcq, E;Joye, P;Cardenas De La Hoz, E;Deben, C;Gasparini, A;Montay-Gruel, P;Le Compte, M;Lion, E;Lardon, F;Van Laere, S;Siozopoulou, V;Campillo-Davo, D;De Waele, J;Pauwels, P;Jacobs, J;Smits, E;Van Audenaerde, JRM;
Journal of hematology & oncology
Species: Human
Sample Types: Whole Tissue
Applications: Immunohistochemistry -
CD70 is Consistently Expressed in Primary and Metastatic Clear Cell Renal Cell Carcinoma
Authors: Huang, RR;Chen, Z;Kroeger, N;Pantuck, A;Said, J;Kluger, HM;Shuch, B;Ye, H;
Clinical genitourinary cancer
Species: Human
Sample Types: Whole Tissue
-
The dual role of CD70 in B‐cell lymphomagenesis
Authors: Man Nie, Weicheng Ren, Xiaofei Ye, Mattias Berglund, Xianhuo Wang, Karin Fjordén et al.
Clinical and Translational Medicine
Species: Human
Sample Types: Whole Tissue
Applications: Immunohistochemistry -
CD70 antibody-drug conjugate as a potential therapeutic agent for uterine leiomyosarcoma
Authors: R Nakae, S Matsuzaki, S Serada, K Matsuo, M Shiomi, K Sato, Y Nagase, S Matsuzaki, S Nakagawa, K Hiramatsu, A Okazawa, T Kimura, T Egawa-Taka, E Kobayashi, Y Ueda, K Yoshino, T Naka, T Kimura
Am. J. Obstet. Gynecol., 2020-08-19;0(0):.
Species: Human
Sample Types: Whole Tissue
Applications: IHC -
Screening a Broad Range of Solid and Haematological Tumour Types for CD70 Expression Using a Uniform IHC Methodology as Potential Patient Stratification Method
Authors: T Flieswasse, V Camara-Cla, A Danu, J Bosq, V Ribrag, P Zabrocki, L Van Rompae, H de Haard, K Zwaenepoel, E Smits, P Pauwels, J Jacobs
Cancers (Basel), 2019-10-22;11(10):.
Species: Human
Sample Types: Whole Tissue
Applications: IHC-P -
Targeted alpha therapy using a novel CD70 targeted thorium-227 conjugate in in vitro and in vivo models of renal cell carcinoma
Authors: UB Hagemann, D Mihaylova, SR Uran, J Borrebaek, D Grant, RM Bjerke, J Karlsson, AS Cuthbertso
Oncotarget, 2017-01-01;0(0):.
Species: Mouse
Sample Types: Whole Tissue
Applications: IHC -
The dual role of CD70 in B‐cell lymphomagenesis
Authors: Man Nie, Weicheng Ren, Xiaofei Ye, Mattias Berglund, Xianhuo Wang, Karin Fjordén et al.
Clinical and Translational Medicine
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Human CD27 Ligand/TNFSF7 Antibody
Average Rating: 4 (Based on 1 Review)
Have you used Human CD27 Ligand/TNFSF7 Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
